Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Placebo controlled trials in neuromyelitis optica are needed and ethical.
The poor recovery of neuromyelitis optica spectrum disorder is associated with a lower level of CXCL12 in the human brain.
Clinical Feasibility of Synthetic MRI in Multiple Sclerosis: A Diagnostic and Volumetric Validation Study.
Physical rehabilitation interventions in nonambulatory people with multiple sclerosis: a systematic review.
Neurodegeneration: Active astrocytes drive inflammation.
Neurogenic vision loss: Causes and outcome. An experience from a tertiary center in Northern India.
Attention-Deficit/Hyperactivity Disorder in Offspring of Mothers With Inflammatory and Immune System Diseases.
Ligands for Ser/Thr phosphoprotein phosphatases: a patent review (2005-2015).
In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology.
Increased disease severity in non-Western immigrants with multiple sclerosis in Oslo, Norway.
Neurological involvement in primary sjögren syndrome: a focus on central nervous system.
Localisation of citrullinated proteins in normal appearing white matter and lesions in the central nervous system in multiple sclerosis.
Multiple sclerosis: Reactivation of Epstein-Barr or herpes viruses not associated with MS relapse.
Risk of venous thrombosis in patients with major illnesses: Results from the MEGA study.
Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study.
Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis.
Magnitude and concurrence of anxiety and depression among attendees with multiple sclerosis at a tertiary care Hospital in Oman.
Clinical and radiological features of recurrent demyelination following acute disseminated encephalomyelitis (ADEM).
Using conceptual work products of case management to design health IT.
Production of IL-27 in multiple sclerosis lesions by astrocytes and myeloid cells: Modulation of local immune responses.
Correction: deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model.
Production and use of lentivirus to selectively transduce primary oligodendrocyte precursor cells for in vitro myelination assays.
Targeting the low-hanging fruit of neurodegeneration.
Immune Tolerance Induction against Experimental Autoimmune Encephalomyelitis (EAE) Using A New PLP-B7AP Conjugate that Simultaneously Targets B7/CD28 Costimulatory Signal and TCR/MHC-II Signal.
[Treatment of neuromyelitis optica].
Pages
« first
‹ previous
…
533
534
535
536
537
538
539
540
541
…
next ›
last »